Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors

Exelixis, the?Exelixis?logo, CABOMETYX, COMETRIQ and COTELLIC are registered?U.S.?trademarks. MINNEBRO is a Japanese trademark.
View source version on?businesswire.com:?https://www.businesswire.com/news/home/20210405005210/en/
Investors Contact: Susan Hubbard EVP, Public Affairs and Investor Relations Exelixis, Inc. (650) 837-8194 shubbard@exelixis.com Media Contact: Lindsay Treadway Executive Director, Public Affairs and Advocacy Relations Exelixis, Inc. (650) 837-7522 ltreadway@exelixis.com Source:?Exelixis, Inc.